Galectin-3 is linked to peripheral artery disease severity, and urinary excretion is associated with long-term mortality
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 341, 7-12
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Differences in galectin-3, a biomarker of fibrosis, between participants with peripheral artery disease and participants with normal ankle–brachial indexVascular Medicine, 2016
- Galectin-3 Predicts Long-Term Cardiovascular Death in High-Risk Patients With Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2015
- Renal function largely influences Galectin-3 prognostic value in heart failureInternational Journal of Cardiology, 2014
- Elevated Galectin-3 Precedes the Development of CKDJournal of the American Society of Nephrology, 2013
- Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient miceGlycobiology, 2013
- Galectin-3 in Cardiac Remodeling and Heart FailureCurrent Heart Failure Reports, 2010
- Mortality and Vascular Morbidity in Older Adults With Asymptomatic Versus Symptomatic Peripheral Artery DiseaseCirculation, 2009
- Galectin-3 in urine of cancer patients: stage and tissue specificityJournal of Cancer Research and Clinical Oncology, 2008
- Galectin-3 Gene Inactivation Reduces Atherosclerotic Lesions and Adventitial Inflammation in ApoE-Deficient MiceThe American Journal of Pathology, 2008
- Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)European Journal of Vascular and Endovascular Surgery, 2007